Jason Westin

Peer-Reviewed Articles

1. Pinnix CC, Dabaja BS, Gunther JR, Fang PQ, Wu SY, Nastoupil LJ, Strati P, Nair R, Ahmed S, Steiner R, Westin J, Neelapu S, Rodriguez MA, Lee HJ, Wang M, Flowers C, Feng L, Esmaeli B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 10(9):1195-1203, 2024. e-Pub 2024. PMID: 38990564.
2. Gurumurthi A, Chin CK, Feng L, Fowler NH, Strati P, Hagemeister FB, Fayad LE, Westin JR, Obi C, Arafat J, Nair R, Steiner RE, Neelapu SS, Flowers CR, Nastoupil LJ. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial. EClinicalMedicine 74:102747, 2024. e-Pub 2024. PMID: 39161543.
3. Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol:JCO2302786. e-Pub 2024. PMID: 39094076.
4. Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
5. Nze C, Andersen CR, Ayers AA, Westin J, Wang M, Iyer S, Ahmed S, Pinnix C, Vega F, Nguyen L, McNeill L, Nastoupil LJ, Zhang K, Bauer CX, Flowers CR. Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL. Blood Adv 8(14):3825-3837, 2024. PMID: 38607394.
6. Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk J, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Adv 8(11):2982-2990, 2024. e-Pub 2024. PMID: 38315832.
7. Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
8. Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma 65(5):1-5, 2024. e-Pub 2024. PMID: 38248629.
9. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. e-Pub 2023. PMID: 37985359.
10. Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, Hamadani M, Westin JR, Bachanova V. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma. Transplant Cell Ther 30(2):241.e1-241.e8, 2024. e-Pub 2023. PMID: 37898374.
11. Davis RE, Westin JR. Degradation trumps mutations in cancer. Science 383(6682):480-481, 2024. e-Pub 2024. PMID: 38301021.
12. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2023. PMID: 37822075.
13. Filosto S, Vardhanabhuti S, Canales MA, Poiré X, Lekakis LJ, de Vos S, Portell CA, Wang Z, To C, Schupp M, Poddar S, Trinh T, Warren CM, Aguilar EG, Budka J, Cheng P, Chou J, Bot A, Shen RR, Westin JR. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). Blood Cancer Discov 5(1):21-33, 2024. PMID: 37983485.
14. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
15. Lionel AC, Westin J. Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma. Curr Oncol Rep 25(11):1387-1396, 2023. e-Pub 2023. PMID: 37861914.
16. Li X, Henderson J, Gordon MJ, Sheikh I, Nastoupil LJ, Westin J, Flowers C, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41(11):1835-1837, 2023. e-Pub 2023. PMID: 37738975.
17. Gurumurthi A, Westin J, Subklewe M. The race is on: bispecifics vs CAR T-cells in B-cell lymphoma. Blood Adv 7(19):5713-5716, 2023. e-Pub 2023. PMID: 37037004.
18. Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin J, Lossos IS, Munoz JL, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv 7(20):6055-6065, 2023. e-Pub 2023. PMID: 37581593.
19. Westin JR, To C, Locke FL. Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply. N Engl J Med 389(12):1152-1153, 2023. PMID: 37733323.
20. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. PMID: 37586321.
21. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL, ZUMA-7 Investigators, Kite Members. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 389(2):148-157, 2023. e-Pub 2023. PMID: 37272527.
22. Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clin Cancer Res 29(10):1894-1905, 2023. PMID: 36999993.
23. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2023. e-Pub 2022. PMID: 36375046.
24. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
25. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
26. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
27. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
28. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2022. PMID: 36068929.
29. Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 41(1):210-225.e5, 2023. e-Pub 2022. PMID: 36584673.
30. Chiu CY, Zhang HC, Westin J, Hosing C, Torres HA. Hepatitis E Virus Infection in Cancer Patients. Transplant Cell Ther 28(11):788.e1-788.e5, 2022. e-Pub 2022. PMID: 36031077.
31. Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
32. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. PMID: 36384092.
33. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
34. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
35. Cherng HJ, Westin JR. Broadening the MIND: tafasitamab and lenalidomide versus synthetic controls. Clin Cancer Res 28(18):3908-3910, 2022. e-Pub 2022. PMID: 35861632.
36. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
37. Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 6(16):4816-4820, 2022. e-Pub 2022. PMID: 35687492.
38. Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2022. PMID: 34758610.
39. Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, Agarwal S, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Morschhauser F. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Clin Lymphoma Myeloma Leuk 22(7):504-512, 2022. e-Pub 2021. PMID: 35151584.
40. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
41. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
42. Westin J, Sehn LH. CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?. Blood 139(18):2737-2746, 2022. e-Pub 2022. PMID: 35240677.
43. Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum KA, Cashen AF, Casulo C, Friedberg JW, Johnston PB, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan PM, Westin JR, Koff JL, Flowers CR. Improving eligibility criteria for first-line trials for patients with DLBCL using a U.S.-based Delphi-method survey. Blood Adv 6(9):2745-2756, 2022. e-Pub 2022. PMID: 35100356.
44. Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
45. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107(3):690-701, 2022. e-Pub 2022. PMID: 33792219.
46. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
47. Westin J. Always be prepared for success. Blood 139(13):1928-1930, 2022. PMID: 35357477.
48. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386(7):640-654, 2022. e-Pub 2021. PMID: 34891224.
49. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 386(7):629-639, 2022. e-Pub 2021. PMID: 34904798.
50. Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 6(4):1143-1151, 2022. e-Pub 2022. PMID: 35015819.
51. Gutierrez C, Brown ART, May HP, Beitinjaneh A, Stephens RS, Rajendram P, Nates JL, Pastores SM, Dharshan A, de Moraes AG, Hensley MK, Feng L, Brudno JN, Athale J, Ghosh M, Kochenderfer JN, Arias AS, Lin Y, McEvoy C, Mead E, Westin J, Kostelecky N, Mian A, Herr MM. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. Crit Care Med 50(1):81-92, 2022. e-Pub 2021. PMID: 34259446.
52. Westin J, Maris MB, Jacobson CA, Patel P, Lakhani N, Harb W, Patel-Donnelly D, McCaul K, Escobar C, Klencke B, Al-Katib AM. Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 22(1):52-59, 2022. e-Pub 2021. PMID: 34454850.
53. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):1-10, 2022. e-Pub 2021. PMID: 34435552.
54. Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39(12):1537-1547, 2021. e-Pub 2021. PMID: 34294911.
55. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma 62(14):1-11, 2021. e-Pub 2021. PMID: 34365878.
56. Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol 8(11):e818-e827, 2021. e-Pub 2021. PMID: 34634256.
57. Gordon MJ, Westin JR. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?. Leuk Lymphoma:1-11. e-Pub 2021. PMID: 34842019.
58. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
59. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):1-8, 2021. e-Pub 2021. PMID: 33942701.
60. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(10):1403-1415, 2021. e-Pub 2021. PMID: 34516954.
61. Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 96(10):1295-1312, 2021. e-Pub 2021. PMID: 34310745.
62. Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, Nabet BY, Soo J, Scherer F, Craig AFM, Casasnovas O, Westin JR, Gaidano G, Rossi D, Roschewski M, Wilson WH, Meignan M, Diehn M, Alizadeh AA. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. J Clin Oncol 39(23):JCO2002573, 2021. e-Pub 2021. PMID: 33909455.
63. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. PMID: 34264268.
64. Cherng HJ, Westin J. Why R-CHOP?+?X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leuk Lymphoma 62(6):1-17, 2021. e-Pub 2021. PMID: 33403905.
65. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
66. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
67. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
68. Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 109(5):1414-1420, 2021. e-Pub 2020. PMID: 33309978.
69. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2020. PMID: 32932518.
70. Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol 192(2):e38-e42, 2021. e-Pub 2020. PMID: 33152104.
71. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32628087.
72. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
73. Brown ART, Jindani I, Melancon J, Erfe R, Westin J, Feng L, Gutierrez C. ICU Resource Utilization in Critically Ill Patients Following Chimeric Antigen Receptor T-Cell Therapy. Am J Respir Crit Care Med 202(8):1184-1187, 2020. e-Pub 2020. PMID: 32530704.
74. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 38(27):JCO1902104, 2020. e-Pub 2020. PMID: 32401634.
75. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open 3(9):e2013935, 2020. e-Pub 2020. PMID: 32990738.
76. Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk 20(8):533-541, 2020. e-Pub 2020. PMID: 32291233.
77. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. PMID: 32822484.
78. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2019. PMID: 31601688.
79. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. PMID: 32589728.
80. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 4(13):3123-3127, 2020. PMID: 32645136.
81. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1380-1387, 2020. e-Pub 2020. PMID: 31971032.
82. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
83. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. PMID: 32191807.
84. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2019. PMID: 31533521.
85. Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 4(4):629-637, 2020. PMID: 32074277.
86. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2019. PMID: 31073068.
87. Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma 61(1):1-5, 2020. e-Pub 2019. PMID: 31373240.
88. Ou A, Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, Michelhaugh S, Brenner A, Pandey M, Kesari S, Korn WM, Mittal S, Westin J, Heimberger AB. Primary CNS lymphoma commonly expresses immune response biomarkers. Neurooncol Adv 2(1):vdaa018, 2020. e-Pub 2020. PMID: 32201861.
89. Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. Clin Lymphoma Myeloma Leuk 19(11):709-714, 2019. e-Pub 2019. PMID: 31446000.
90. Myers AL, Kawedia JD, Nader A, Westin JR, Shank BR. A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient. J Clin Pharm Ther 44(5):800-804, 2019. e-Pub 2019. PMID: 31111511.
91. Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol 42(10):789-796, 2019. e-Pub 2019. PMID: 31478934.
92. Westin J. Ibrutinib and lenalidomide: when 1+1 = >2. Blood 134(13):996-998, 2019. PMID: 31558554.
93. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
94. Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, Tiwari R, Anak Ö, Awasthi R, Pacaud L, Romanov VV, Schuster SJ. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv 3(14):2230-2236, 2019. PMID: 31332046.
95. Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell 178(3):699-713.e19, 2019. e-Pub 2019. PMID: 31280963.
96. Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Amini B, Neelapu S, Lee HJ, Westin J, Fowler N, Nastoupil L, Dabaja B. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 104(2):447-455, 2019. e-Pub 2019. PMID: 30769175.
97. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
98. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882, 2019. e-Pub 2019. PMID: 30919940.
99. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. Ann Hematol 98(5):1169-1176, 2019. e-Pub 2019. PMID: 30617643.
100. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 41(5):1546, 2019. e-Pub 2019. PMID: 30990235.
101. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. PMID: 31036721.
102. Nowakowski GS, Feldman T, Rimsza LM, Westin JR, Witzig TE, Zinzani PL. Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer J 9(6):48, 2019. e-Pub 2019. PMID: 31097684.
103. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol 185(2):334-338, 2019. e-Pub 2018. PMID: 29978452.
104. Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res 7(4):644-657, 2019. e-Pub 2019. PMID: 30745366.
105. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clin Lymphoma Myeloma Leuk 19(4):244-250, 2019. e-Pub 2019. PMID: 30686775.
106. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Reply to J. Wang et al. J Clin Oncol 37(9):755-757, 2019. e-Pub 2019. PMID: 30753108.
107. Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist 24(2):219-228, 2019. e-Pub 2018. PMID: 30108156.
108. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. e-Pub 2018. PMID: 30360985.
109. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT, JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45-56, 2019. e-Pub 2018. PMID: 30501490.
110. Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book 39:433-444, 2019. e-Pub 2019. PMID: 31099694.
111. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma 59(12):1-8, 2018. e-Pub 2018. PMID: 29697005.
112. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol DOI: 10.1200/JCO.2018.78.5246(28):2845-2853, 2018. e-Pub 2018. PMID: 30125215.
113. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol 182(5):718-723, 2018. e-Pub 2017. PMID: 28771675.
114. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res 24(16):3967-3980, 2018. e-Pub 2018. PMID: 29666304.
115. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 40(6):1335, 2018. e-Pub 2018. PMID: 29851218.
116. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2(11):1334-1343, 2018. PMID: 29895624.
117. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget 9(48):28897-28902, 2018. e-Pub 2018. PMID: 29988979.
118. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. e-Pub 2018. PMID: 29785709.
119. Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol 181(2):264-267, 2018. e-Pub 2017. PMID: 28419407.
120. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28792260.
121. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
122. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2017. PMID: 28925994.
123. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2017. PMID: 29196178.
124. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
125. Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 9(1):346-360, 2018. e-Pub 2017. PMID: 29416618.
126. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol 179(5):851-854, 2017. e-Pub 2016. PMID: 27502933.
127. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma 58(12):1-12, 2017. e-Pub 2017. PMID: 28482717.
128. Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, Wei P, Tang G, Seegmiller AC, Reddy NM, Yin CC, Wang W, Xu J, Miranda RN, Zuo Z, Li S. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol 30(12):1688-1697, 2017. e-Pub 2017. PMID: 28776574.
129. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531-2544, 2017. e-Pub 2017. PMID: 29226797.
130. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2016. PMID: 27378601.
131. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800-1808, 2017. e-Pub 2017. PMID: 28774879.
132. Li X, Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, Fowler N, Miranda RN, Zhang M, Ferry JA, Medeiros LJ, Harris NL, Young KH. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol 41(10):1309-1321, 2017. PMID: 28817403.
133. Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood 130(8):995-1006, 2017. e-Pub 2017. PMID: 28646116.
134. Fanale MA, Cheah C, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemesiter F, Samaniego F, Rodriguez MA, Neelapu S, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz S, Younes A. Potential Improvement of Clinical Outcomes for Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated With R-CHOP, 2017.
135. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood 130(4):472-477, 2017. e-Pub 2017. PMID: 28522441.
136. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
137. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
138. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
139. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
140. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):1365-2141, 2017. e-Pub 2016. PMID: 27983760.
141. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
142. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
143. Issa AK, Westin JR. What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk 16(9):483-487, 2016. e-Pub 2016. PMID: 27364263.
144. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. e-Pub 2016. PMID: 27227654.
145. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. e-Pub 2016. PMID: 27091808.
146. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2015. PMID: 26795083.
147. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. e-Pub 2016. PMID: 26802151.
148. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. e-Pub 2015. PMID: 26648336.
149. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim J, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, Dimopoulos M, Moreau P, Anderson K, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson P. Management of relapsed multiple myeloma: Recommendations of the international myeloma working group. Leukemia. e-Pub 2015. PMID: 26710887.
150. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. e-Pub 2015. PMID: 26640039.
151. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by (18)Fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys 92(1):113-121, 2015. PMID: 25863759.
152. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-182, 2015. PMID: 25863764.
153. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. e-Pub 2015. PMID: 25754633.
154. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. e-Pub 2015. PMID: 25820332.
155. Westin JR. Busting Robustness: Using Cancer's Greatest Strength to Our Advantage. Future Oncology 11(1):73-77, 2015. PMID: 24673642.
156. Bui PL, Vicens RA, Westin JR, Jensen CT. Multimodality imaging of Epstein-Barr virus-associated inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: case report and literature review. Clin Imaging. e-Pub 2015. PMID: 25725946.
157. Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol 168(6):784-785. e-Pub 2014. PMID: 25529575.
158. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
159. Westin JR. Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma. Clin Lymphoma Myeloma Leuk 14(5):335-342, 2014. e-Pub 2014. PMID: 24650973.
160. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programmed for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 2014. e-Pub 2014. PMID: 25039868.
161. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
162. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomized, phase 1b study. Lancet Oncol 15(9):1019-26, 2014. e-Pub 2014. PMID: 25042202.
163. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated Therapeutic Progress in Diffuse Large B-cell Lymphoma. Ann Hematol 93(4):541-56, 2014. e-Pub 2013. PMID: 24375125.
164. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. e-Pub 2013. PMID: 24332512.
165. Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver N, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 2014. PMID: 25401088.
166. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 54(12):2631-8, 2013. e-Pub 2013. PMID: 23488661.
167. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
168. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 2013. e-Pub 2012. PMID: 23276888.
169. Westin JR, Kurzrock R. It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. Mol Cancer Ther 11(12):2549-55, 2012. e-Pub 2012. PMID: 23204432.
170. Westin JR, Gibbs A, Mills KR, Neelapu SS. Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula. Case Report Med 2012:457908, 2012. e-Pub 2012. PMID: 22811723.
171. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol 2:188, 2012. e-Pub 2012. PMID: 23248775.
172. Davis RE, Westin JR. Vive la resistance: stem cells in mantle cell lymphoma. Leuk Lymphoma 52(6):944-5, 2011. e-Pub 2011. PMID: 21463111.
173. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 2011. PMID: 22110505.
174. Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. Leuk Lymphoma 51(1):161-3, 2010. PMID: 19863175.
175. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep 4(4):218-24, 2009. PMID: 20425411.

Editorials

1. Westin JR. Busting robustness: using cancer's greatest strength to our advantage. Future Oncol. PMID: 24673642.
2. Westin J, Hagemeister F. R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?. J Comp Eff Res 2(6):537-40, 2013. PMID: 24236792.

Abstracts

1. Frederick L. Locke, MD1, David B. Miklos, MD, PhD2, Caron Jacobson, MD3, Miguel-Angel Perales, MD4, Marie José Kersten, MD, PhD5, Olalekan O. Oluwole, MBBS, MPH6, Armin Ghobadi, MD7*, Aaron P. Rapoport, MD8, Joseph P. McGuirk, DO9, John M. Pagel, MD, PhD10, Javier Muñoz, MD, MS, MBA, FACP11*, Umar Farooq, MD12, Tom Van Meerten, MD, PhD13*, Patrick M. Reagan, MD14, Anna Sureda15, Ian W. Flinn, MD, PhD16, Peter Vandenberghe, MD, PhD17, Kevin Song, MD, FRCPC18, Michael Dickinson, MBBS19, Monique C. Minnema, MD20, Peter A. Riedell, MD21, Lori A. Leslie, MD22*, Sridhar Chaganti, MD23*, Yin Yang, MS, MD24*, Simone Filosto, PhD24*, Marco Schupp, MD24*, Christina To, MD24*, Paul Cheng, MD, PhD24, Leo I. Gordon, MD25 and Jason R. Westin, MD26. Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Blood 138, 2021.
2. Hua-Jay J. Cherng, Ryan Sun, Haopeng Yang, Qing Deng, Luis Fayad, Nathan H. Fowler, Simrit Parmar, Sairah Ahmed, Raphael E Steiner, Fredrick B. Hagemeister, Hun Ju Lee, Ranjit Nair, Maria Alma Rodriguez, Felipe Samaniego, Swaminathan P Iyer, Loretta Nastoupil, Sattva S. Neelapu, Paolo Strati, Jason R. Westin, Michael R Green. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. Blood 138, 2021.
3. Anita Kumar, Jason R. Westin, Stephen J. Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Devin Copley, Clare Grieve, Allison P. Jacob, Ashlee Joseph, Leana Laraque, Gita Masand, Chelsea D Mullins, Ellen Napier, Tania Rodriguez, Venkatraman Seshan, Shreya Vemuri, Andrew D. Zelenetz. A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. Blood 138, 2021.
4. Jay Y. Spiegel, Michael D. Jain, Loretta Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, Andre H. Goy, Brian T. Hill, Charalambos Andreadis, Javier Muñoz, Matthew L. Ulrickson, Jason R. Westin, Julio C. Chavez, Miriam T. Jacobs, N Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Saurabh Dahiya, Matthew A. Lunning. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. Blood 138, 2021.
5. Sushanth Gouni, Jason R. Westin, Haleigh Mistry, Raphael Eric Steiner, Jinsu James, Simrit Parmar, Mansoor Noorani, Nathan H. Fowler, Sandra B. Horowitz, Lei Feng, Luis E. Fayad, Swaminathan P Iyer, Michael R Green, Misha Hawkins, Christopher R. Flowers, Sairah Ahmed, Loretta Nastoupil, Sattva S. Neelapu, Yago Nieto, Paolo Strati. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. Blood 138, 2021.
6. Ajlan Al Zaki, Jason R. Westin, Grace Watson, Lei Feng, Sairah Ahmed, Haleigh Mistry, Loretta Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P Iyer, Hun Lee, Raphael E Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Paolo Strati. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. Blood 138, 2021.
7. Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunther, Penny Fang, Susan Wu, Loretta Nastoupil, Paolo Strati, Ranjit Nair, Sairah Ahmed, Raphael E Steiner, Luis Malpica-Castillo, Dai Chihara, Preetesh Jain, Luis Fayad, Jason R. Westin, Sattva S. Neelapu, Maria Alma Rodriguez, Fredrick B. Hagemeister, Hun Ju Lee, Michael Wang, Felipe Samaniego, Nathan H. Fowler, Christopher R. Flowers, Lei Feng, Linda Chi, Bita Esmaeli. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. Blood 138, 2021.
8. Dai Chihara, Loretta Nastoupil, Paolo Strati, Felipe Samaniego, Lei Feng, Maria Alma Rodriguez, Luis Fayad, Jason R. Westin, Fredrick B. Hagemeister, Michael Wang, Sattva S. Neelapu, Nathan H. Fowler. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma. Blood 138, 2021.
9. Jason R. Westin, Raphael Steiner, Lei Feng, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Loretta Nastoupil, Dai Chihara, Fredrick B. Hagemeister, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Eric Davis, Michael R Green. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. Blood 138, 2021.
10. Raphael E Steiner, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Michael R Green, Loretta Nastoupil, Fredrick B. Hagemeister, Lei Feng, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Jason R. Westin. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. Blood 138, 2021.
11. Ranjit Nair, Nafis Deen, Sairah Ahmed, Roberto N. Miranda, Nathan H. Fowler, Luis Fayad, Raphael E Steiner, Fredrick B. Hagemeister, Maria Alma Rodriguez, Hun Ju Lee, Paolo Strati, Luis Malpica-Castillo, Dai Chihara, Preetesh Jain, Jillian R. Gunther, Christopher R. Flowers, L. Jeffrey Medeiros, Yago Nieto, Jeremy L. Ramdial, Sattva S. Neelapu, Loretta Nastoupil, Michael R Green, Michael Wang, Francisco Vega, Lei Feng, Swaminathan Padmanabhan Iyer, Jason R. Westin. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood 138, 2021.
12. David M. Kurtz, Jacob J. Chabon, Joanne Soo, Lyron Co Ting Keh, Stefan Alig, Andre Schultz, Michael C. Jin, Florian Scherer, Alexander F. Craig, Chih Long Liu, Ulrich Duehrsen, Andreas Huettmann, René-Olivier Casasnovas, Jason Westin, Mark J. Roschewski, Wyndham H. Wilson, Gianluca Gaidano, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh. Phased variants improve DLBCL minimal residual disease detection at the end of therapy. Journal of Clinical Oncology 39, 2021.
13. Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, Josée M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMSc, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD. Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. Blood 136, 2020.
14. Paolo Strati, MD, Felipe Samaniego, MD, Mariana Gallardo, Mansoor Noorani, F. B. B. Hagemeister, MD, Jason R. Westin, MD, Hun Ju Lee, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Jillian R. Gunther, MD PhD, Rashmi Kanagal-Shamanna, MD, Francisco Vega, MDPhD, Nathan H Fowler, MD, Chris R. Flowers, MD MS, Loretta J. Nastoupil, MD. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. Blood 136, 2020.
15. Preetesh Jain, MBBS,MDDM,PhD, Guilin Tang, MD, C. Cameron Yin, MD PhD, Chi Young Ok, MD, Lucy Navsaria, MB BCh BAO, Maria Badillo, MSN, RN, OCN, CCRP, Wendy Chen, Yijing Li, MS, Yuxuan Che, Yang Liu, PhD, Onyeka Oriabure, Graciela M. Nogueras González, MPH, Jason Westin, MD, Loretta J. Nastoupil, MD, Sairah Ahmed, MD, Ranjit Nair, Selvi Thirumurthi, Shaoying Li, MD, Rashmi Kanagal-Shamanna, MD, Francisco Vega, MDPhD, Christopher Flowers, MDMS, Michael Wang, MD. Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients. Blood 136, 2020.
16. Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, Josée M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMSc, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD. Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. Blood 136, 2020.
17. Samer A. Srour, MD MS, Jie Xu, MD, Taha Al-Juhaishi, MD, Raphael Eric Steiner, MD, Joe Ensor, PhD, Sairah Ahmed, MD, Simrit Parmar, MD, MSCI, Paolo Strati, MD, Loretta J. Nastoupil, MD, Yago Nieto, MD, Chitra Hosing, MD, Hun Ju Lee, MD, Jason Westin, MD, Nathan H. Fowler, MD, Luis Fayad, Bouthaina S. Dabaja, MD, Chelsea C. Pinnix, MD PhD, Jillian R. Gunther, MD PhD, Penny Fang, MD, Felipe Samaniego, MD, Preetesh Jain, MBBS,MDDM,PhD, Richard E. Champlin, MD, Issa F. Khouri, MD, Michael Wang, MD, Roberto N. Miranda, MD, Francisco Vega, MDPhD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Swami P. Iyer, MD. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood 136, 2020.
18. Tycel J. Phillips, MD, Adam J Olszewski, MD, Javier Munoz, MD, Tae Min Kim, MD PhD, Dok Hyun Yoon, Richard Greil, MD, Jason Westin, MD, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O'Hear, Raluca Negricea, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, Anusha Vallurupalli. Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. Blood 136, 2020.
19. Michael Wang, MD, Preetesh Jain, MBBS,MDDM,PhD, Yixin Yao, PhD, Yang Liu, PhD, Shuangtao Zhao, PhD, Holly Hill, Omar Moghrabi, Hun Ju Lee, MD, Felipe Samaniego, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Wendy Chen, Onyeka Oriabure, Yuxuan Che, Yijing Li, MS, Lei Feng, MS, Graciela M. Nogueras González, MPH, Guofang Xu, MD, Nicolaus Wagner-Bartak, MD, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Francisco Vega, MDPhD, C. Cameron Yin, MD PhD, Michelle Avellaneda, Maria Badillo, MSN, RN, OCN, CCRP, Christopher Flowers, MDMS, Linghua Wang, PhD. Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. Blood 136, 2020.
20. Preetesh Jain, MBBS,MDDM,PhD, Shaojun Zhang, PhD, Rashmi Kanagal-Shamanna, MD, Lucy Navsaria, MB BCh BAO, Chi Young Ok, MD, Guilin Tang, MD, C. Cameron Yin, MD PhD, Maria Badillo, MSN, RN, OCN, CCRP, Wendy Chen, Onyeka Oriabure, Hun Ju Lee, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Omar Moghrabi, Yuxuan Che, Felipe Samaniego, MD, Sairah Ahmed, MD, Ranjit Nair, Shaoying Li, MD, Francisco Vega, MDPhD, Christopher Flowers, MDMS, Linghua Wang, PhD, Michael Wang, MD. Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. Blood 136, 2020.
21. Anita Kumar, MD, Jason Westin, MD, Stephen J Schuster, MD, Grzegorz S. Nowakowski, MD, Izidore S. Lossos, MD, Connie Lee Batlevi, MDPhD, Philip Caron, MD PhD, Pamela Drullinsky, MD, John Gerecitano, MD PhD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Allison P. Jacob, Erel Joffe, MD MSc, Ashlee Joseph, Gottfried R. von Keudell, MD PhD, Leana Laraque, BA, Oscar B Lahoud, MD, Matthew J Matasar, MD, Craig H. Moskowitz, MD, Chelsea D Mullins, BS, Ariela Noy, MD, Colette Owens, MD, Maria Lia Palomba, Carol S. Portlock, MD, Ildefonso Rodriguez-Rivera, MD, Gilles Salles, MDPhD, Venkatraman Seshan, PhD, David J. Straus, MD, Shreya Vemuri, Anas Younes, Andrew D Zelenetz, MD PhD. Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. Blood 136, 2020.
22. Preetesh Jain, MBBS,MDDM,PhD, Yixin Yao, PhD, Shuangtao Zhao, PhD, Yang Liu, PhD, Holly Hill, Yuxuan Che, Yijing Li, MS, Alexa A Jordan, BS, Joseph McIntosh, BS, Hun Ju Lee, MD, Raphael Eric Steiner, MD, Felipe Samaniego, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Ranjit Nair, Sairah Ahmed, MD, Chi Young Ok, MD, Rashmi Kanagal-Shamanna, MD, Onyeka Oriabure, Guofang Xu, MD, Wendy Chen, Omar Moghrabi, Chloe Marie McClain, Maria Badillo, MSN, RN, OCN, CCRP, Selvi Thirumurthi, David Santos, Cezar Iliescu, MD, C. Cameron Yin, MD PhD, Shaoying Li, MD, Guilin Tang, MD, Francisco Vega, MDPhD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Linghua Wang, PhD, Michael Wang, MD. Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial. Blood 136, 2020.
23. Paolo Strati, MD, Haleigh Mistry, Brittany Pulsifer, Luis Fayad, Sairah Ahmed, MD, Hun Ju Lee, MD, Swami P. Iyer, MD, Ranjit Nair, MD, Loretta J. Nastoupil, MD, Simrit Parmar, MD, MSCI, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael Wang, MD, Chelsea C. Pinnix, MD PhD, Bouthaina S. Dabaja, MD, Mansoor Noorani, Catherine M. Claussen, MS, Elizabeth J. Shpall, MD, Partow Kebriaei, MD, Chris R. Flowers, MD MS, Jason R. Westin, MD, Sattva S. Neelapu, MD. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 136, 2020.
24. Swami P. Iyer, MD, Jie Xu, MD, Melody R. Becnel, MD, Ranjit Nair, MD, Raphael Steiner, MD, Lei Feng, MS, Hun Ju Lee, MD, Paolo Strati, MD, Sairah Ahmed, MD, Simrit Parmar, MD, MSCI, Yago Nieto, MD, Chitra Hosing, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Ann Vo, Felipe Samaniego, MD, Nathan H. Fowler, MD, Neeraj Saini, MD, Issa F. Khouri, MD, Jin S. Im, Preetesh Jain, MBBS,MDDM,PhD, Luis Fayad, Michael Wang, MD, Roberto N. Miranda, MD, Francisco Vega, MDPhD, Christopher Flowers, MDMS, Sattva S. Neelapu, MD. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). Blood 136, 2020.
25. Paolo Strati, MD, Grace Watson, Sandra B. Horowitz, Pharm.D., Ranjit Nair, MD, Maria Alma Rodriguez, MD, Raphael Eric Steiner, MD, Luis Fayad, Jason R. Westin, MD, Sattva S. Neelapu, MD. Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel. Blood 136, 2020.
26. Lauren Willis, PharmD, Tristin Abair, PhD, Pan Chen, PhD, Jason Westin, MD. Innovative, Consequence-Based Educational Intervention Improves Hematologists/Oncologists Skills Using CAR T-Cell Therapies for R/R Diffuse Large B-Cell Lymphoma. Blood 136, 2020.
27. Neeraj Saini, MD, Chia-Chi Chang, PhD, Paolo Strati, MD, Loretta J. Nastoupil, MD, Jason Westin, MD, Ranjit Nair, MD, Luis Fayad, Sairah Ahmed, MD, Hun Ju Lee, MD, Swaminathan P Iyer, MD, Raphael Eric Steiner, MD, Uri Greenbaum, MD, Partow Kebriaei, MD, Elizabeth J. Shpall, MD, Nitin Jain, MD, Michael R Green, PhD, Nadim J Ajami, Christopher Flowers, MDMS, Richard E. Champlin, MD, Jennifer Wargo, MD, Sattva S. Neelapu, MD, Robert R. Jenq, MD. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood 136, 2020.
28. Sushanth Gouni, MD, Paolo Strati, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Raphael E Steiner, MD, Ranjit Nair, MD, Luis Fayad, Sattva S. Neelapu, MD, Ralf Landgraf, PhD, Daniel Bilbao, PhD, Francisco Vega, MDPhD, Nitin Agarwal, PhD. Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 136, 2020.
29. Hua-Jay J Cherng, MD, Raphael E Steiner, MD, Luis Fayad, Paolo Strati, MD, Ranjit Nair, MD, F. B. B. Hagemeister, MD, Loretta J. Nastoupil, MD, Hun Ju Lee, MD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Felipe Samaniego, MD, Maria Alma Rodriguez, MD, Lei Feng, MS, Hubert Chuang, MDPhD, Jason R. Westin, MD. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. Blood 136, 2020.
30. Uri Greenbaum, MD, Paolo Strati, MD, Rima M. Saliba, PhD, Janet Torres, Gabriela Rondon, Yago Nieto, MD, Chitra Hosing, MD, Samer A. Srour, MD MS, Jason Westin, MD, Luis Fayad, Hun Ju Lee, MD, Swaminathan P Iyer, MD, Loretta J. Nastoupil, MD, Simrit Parmar, MD, MSCI, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael Wang, MD, Chelsea C. Pinnix, MD PhD, Christopher Flowers, MDMS, Sudhakar Tummala, MD, Jeremy Ramdial, MD, Fevzi F. Yalniz, Misha Hawkins, Katayoun Rezvani, MD PhD, Richard E. Champlin, MD, Elizabeth J. Shpall, MD, Sattva S. Neelapu, MD, Partow Kebriaei, MD, Sairah Ahmed, MD. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood 136, 2020.
31. Jain P, Kanagal-Shamanna R, Ghorab A, Nastoupil L, Fayad LE, Medeiros J, Hu S, Neelapu SS, Westin J, Oki Y, Wang M, Fowler N. Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience. Blood 130:2852, 2017.
32. Chihara D, Fowler N, Oki Y, Fanale M, Nastoupil L, Westin J, Fayad LE, Neelapu SS, Cheah CY. Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. Blood 130:4137, 2017.
33. Chihara D, Dabaja B, Oki Y, Westin J, Cheah CY, Pinnix C, Neelapu S, Fanale M, Fowler N, Nastoupil L. You have accessThe Role of Radiation Therapy and Risk of Developing Secondary Gastric Cancer in Patients Presenting with Early Stage Gastric Lymphoma. Blood 130:1569, 2017.
34. Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta Nastoupil, Sattva S. Neelapu, Luis E. Fayad, Nathan H. Fowler and Chan Yoon Cheah. Stage I Lymphoma: Difference in Survival Outcome By Site of Involvement. Blood 130:1569, 2017.
35. Frederick L. Locke, Jason R. Westin, David B. Miklos, Alex F. Herrara, Caron A. Jacobson, Jennifer Lee, John M. Rossi, Adrian Bot, Allen Xue, Lynn Navale, Jeff S. Aycock, Jeffrey S. Wiezorek and Zachary J. Roberts. Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL). J Clin Oncol 130:2826, 2017.
36. Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler N, Hagemeister F, Kwak L, Lee HJ, Wang M, Westin J, Ruben C, Wesson E, Fanale M. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. Blood 130:4074, 2017.
37. Melody R Becnel, Loretta Nastoupil, R. Eric Davis, F. B. Hagemeister, Michelle A. Fanale, Luis Fayad, Jason R. Westin, Michael Wang, Yasuhiro Oki, Linda Claret, Sheryl G Forbes, Lei Feng, Felipe Samaniego, Sattva S. Neelapu and Nathan Fowler. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. Blood 130:4040, 2017.
38. Nastoupil L, Westin J, Fowler N, Fanale M, Samaniego F, Oki Y, Dsouza L, Obi C, Cao JJ, Cheng X, MA M, Zhiqiang W, Feng F, Zhou S, Davis RE, Neelapu SS. High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study. Blood 130:414, 2017.
39. Westin J, Oki Y, Nastoupil L, Fayad L, Neelapu S, Turturro F, Hagemeister F, Rodriguez MA, Lee HJ, Young K, McDonnell T, Ford RJ, Davis RE. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results. Blood 130:189, 2017.
40. Schroers-Martin JG, Kurtz DM, Soo J, Jin M, Scherer F, Craig A, Chabon JJ, Long Liu C, Stehr H, Duehrsen U, Hüttmann A, Ségolène Cottereau A, Meignan M, Casasnovas O, Westin J, Gaidano G, Rossi D, Advani R, Roschewski M, Wilson W, Diehn M, Alizadeh AA. Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes. Blood 130:4018, 2017.
41. David M. Kurtz, Florian Scherer, Michael Jin, Joanne Soo, Alexander Craig, Mohammad S Esfahani, Jacob J Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron Newman, Jason R. Westin, Gianluca Gaidano, Davide Rossi, Maximilian Diehn and Ash A. Alizadeh. Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. Blood 130:826, 2017.
42. Kurtz DM, Jin M, Soo J, Scherer F, Craig A, Chabon JJ, Schroers-Martin J, Long Liu C, Stehr R, Schmitz C, Duehrsen U, Hüttmann A, Ségolène Cottereau A, Meignan M, Casasnovas O, Westin J, Gaidano G, Rossi D, Roschewski M, Wilson WH, Diehn M, Alizadeh AA. Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study. Blood 130:310, 2017.
43. Richard Thomas Maziarz, Michael R. Bishop, Constantine S. Tam, Peter Borchmann, Ulrich Jaeger, Joseph P. McGuirk, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen Ronan Foley, Isabelle Fleury, Stephan Mielke, Jason R. Westin, Phoebe Joy Ho, Veronika Bachanova, Harald Holte, John M. Magenau, Oezlem Anak, Lida Bubuteishvili Pacaud, Siegbert Guenther, Jie Zhang, Lawrence Rasouliyan, Feng Tai, Gilles Salles and Stephen J. Schuster. Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood 130:5215, 2017.
44. Stephen J. Schuster, Michael R. Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann, Joseph P. McGuirk, Ulrich Jaeger, Samantha Jaglowski, Charalambos Andreadis, Jason R. Westin, Isabelle Fleury, Veronika Bachanova, Stephen Ronan Foley, P. Joy Ho, Stephan Mielke, John M. Magenau, Harald Holte, Koen Van Besien, Marie Jose Kersten, Takanori Teshima, Kensei Tobinai, Paolo Corradini, Oezlem Anak, Lida Bubuteishvili Pacaud, Christopher del Corral, Rakesh Awasthi, Feng Tai, Gilles Salles and Richard Thomas Maziarz. Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood 130:577, 2017.
45. Hu B, Loghavi S, Fayad LE, Noorani M, Fowler NH, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu SS, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of De Novo CD5+ Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era. J Clin Oncol 35, 2017 (suppl; abstr e19019), 2017.
46. Loretta J. Nastoupil, Jason R. Westin, Nathan Hale Fowler, Michelle A. Fanale, Felipe Samaniego, Yasuhiro Oki, Chizobam Obi, JingJing Cao, Xiaoyun Cheng, Man Chun John Ma, Zhiqiang Wang, Fuliang Chu, Lei Feng, Shouhao Zhou, Richard Eric Davis, Sattva Swarup Neelapu;. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study. J Clin Oncol 35, 2017 (suppl; abstr 7519), 2017.
47. Nathan Hale Fowler, Sattva Swarup Neelapu, Felipe Samaniego, Sheryl Forbes, Fredrick B. Hagemeister, Luis Fayad, Lei Feng, Francesco Turturro, Jason R. Westin, Janine Arafat, Eleanor Neal, Loretta J. Nastoupil. Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study. J Clin Oncol 35, 2017 (suppl; abstr 7531), 2017.
48. Michael C. Jin, David Matthew Kurtz, Mohammad Shahrokh Esfahani, Florian Scherer, Alexander F.M. Craig, Joanne Soo, Michael Siavash Khodadoust, Ruth Sharon Saganty, Jacob J. Chabon, Joseph Schroers-Martin, Henning Stehr, Ranjana H. Advani, Davide Rossi, Gianluca Gaidano, Jason R. Westin, Maximilian Diehn, Ash A. Alizadeh. Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. J Clin Oncol 35, 2017 (suppl; abstr 7507), 2017.
49. Sathyanarayanan V, Oki Y, Issa AK,Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez AM, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy—the University of Texas MD Anderson Experience. Blood (2016 ASH Annual Meeting) 128(26):106, 2016.
50. Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W*, Oriabure O*, Huang SY, Li S, Zhang L, Badillo M, Hartig KH*, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. Blood (2016 ASH Annual Meeting) 128(26):147, 2016.
51. Quesada AQ, Desai P, Tang G, Lin P, Westin JR, Seegmiller AC, Yin CC, Wang W, Xu J, Miranda RN, Reddy N, Medeiros LJ, Li S. MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma. Blood (2016 ASH Annual Meeting) 128(26):154, 2016.
52. Havranek O, Xu J, Koehrer S, Wang Z, Comer J, Becker L, Yi AF, Burger JA, Westin JR, Zal T, Davis RE. Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition. Blood (2016 ASH Annual Meeting) 128(26):779, 2016.
53. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Jacobson CA, Westin JR, Chavez JC, Ghobadi A, Herrera AF, LaCasce AS, Bot A, Rossi JM, Jiang Y, Aycock JS, Elias M, Wiezorek J, Go Wy. A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. Blood (2016 ASH Annual Meeting) 128(26):998, 2016.
54. Scherer F, Kurtz DM, Newman AM, Esfahani MS, Craig A, Stehr H, Lovejoy AF, Chabon JJ, Liu CL, Zhou Li, Glover C, Visser BC*, Poultsides G, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Davis ER, Gaidano G, Kunder CA, Rossi D, Westin JR, Diehn M, Alizadeh AA. Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma Clinically Relevant Abstract. Blood (2016 ASH Annual Meeting) 128(26):1089, 2016.
55. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Blood (2016 ASH Annual Meeting) 128(26):1833, 2016.
56. Kurtz DM, Scherer F, Newman AM, Craig A, Jin M, Stehr H, Chabon JJ, Esfahani M, Liu CL, Zhou L, Glover C, Visser BC, Poultsides G, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Davis ER, Kunder CA, Westin JR, Diehn M, Alizadeh AA. Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. Blood (2016 ASH Annual Meeting) 128(26):2930, 2016.
57. Jain P, Kanagal-Shamanna R, San Lucas F, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JE, Medeiros LJ, Fowler N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). Blood (2016 ASH Annual Meeting) 128(26):2975, 2016.
58. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler N, Medeiros LJ, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood (2016 ASH Annual Meeting) 128(26):4153, 2016.
59. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood (2016 ASH Annual Meeting) 128(26):4208, 2016.
60. Neelapu SS, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, Braunschweig I, Oluwole O, Siddiqi T, Lin Y, Timmerman J, Stiff PJ, Friedberg J, Flinn I, Goy A, Smith M, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Reagan P, Bot A, Rossi JM, Navale L, Jiang Y, Aycock JS, Elias M, Wiezorek J, Go WY. Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1. Blood (2016 ASH Annual Meeting) 128(26):LBA-6, 2016.
61. Westin JR, Oki Y, Fayad LE, Nastoupil L, Turturro F, Hagemeister FB, Sathyanarayanan V, Young KH, McDonnell T, Chuang HH, Zhou S, Neelapu SS, Davis RE. Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma. J Clin Oncol 34:TPS7575, 2016.
62. Westin JR, Maris MB, Al-Katib AM, Lakhani NJ, Patel PA, Harb WA, McCaul K, Patel-Donnelly D, Messmann RA, Klencke BJ. A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study. J Clin Oncol 34:TPS7577, 2016.
63. Issa A, Sathyanarayanan V, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH, Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young K, McDonnell T, Pinnix CC, Fayad LE, Westin JR. Outcomes of diffuse large b-cell lymphoma with MYC and/or BCL2 protein expression treated with intensive chemotherapy. J Clin Oncol 34:7563, 2016.
64. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee JL, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (2015 ASH Annual Meeting) 126(123), 2015.
65. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood (2015 ASH Annual Meeting) 126(123), 2015.
66. Chihara D, Oki Y, Westin J, Nastoupil L, Fayad L, Samaniego F, Wesson E, Ruben C, Horowitz S, Feng L, Garg N, Ahmed S, Khouri I, Hosing C, Romaguera J, Fowler N, Fanale M. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Blood (2015 ASH Annual Meeting) 126(123), 2015.
67. Galamina N, Smith S, Liao C, Petrick A, Libao B, Gartenhaus R, Westin J, Cohen K, Knost J, Stadler W, Doyle A, Karrison T, Gordon L, Evens A. Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial. Blood (2015 ASH Annual Meeting) 126(123), 2015.
68. Ahmed M, Oki Y, Noorani M, Nastoupil L, Fayad L, Hagemeister F, Rodriguez A, Davis RE, Westin J. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. Blood (2015 ASH Annual Meeting) 126(123), 2015.
69. Havranek O, Koehrer S, Xu J, Becker L, Comer J, Karri A, Wang Z, Ma W, Westin J, Sal T, Burger J, Davis RE. B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal B-Cell Subtype, Plus Self Antigen-induced in the Activated B-Cell Subtype. Blood (2015 ASH Annual Meeting) 126(123), 2015.
70. Khouri I, Sui D, Turturro F, Erwin W, Basset R, Korbling M, Valverde R, Ahmed S, Alousi A, Anderlini P, Bashir Q, Cuirea S, Oran B, Olson A, Popat U, Patel K, Qazilbash M, Fanale M, Fayad L, Nastoupil L, Westin J, Gulbis A, Medeiros J, Young K, Jessop A. In-Vivo Purging with Rituximab (R) Followed by Z/BEAM vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood (2015 ASH Annual Meeting) 126(123), 2015.
71. Chihara D, Ahmed M, Oki Y, Westin J, Hagemeister F, Romaguera J, Fanale M, Lee HJ, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler N, Wang M, Fayad L, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (2015 ASH Annual Meeting) 126(123), 2015.
72. Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren E. SUVmax on Pre-Treatment FDG PET Scan is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 2014.
73. Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, David RE, Neelapu S. R-Bendamustine vs. R-CHOP as Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 2014.
74. Fayad L, Rodriguez A, Samaniego F, Fowler N, Oki Y, Turturro F, Westin J, Kwak L, Sabaja B, Feng L, Davis RE, Neelapu S. Antibiotic Therapy of H. Pylori negative Gastric MALT Lymphoma. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 2014.
75. Ahmed S, Ciurea SO, Fayad L, Oran B, Parmar S, Popat U, Westin J, Turturro F, Medeiros LJ, Gulbis AM, Young KH. Outcomes Following Allogenic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL) Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B-Cell Lymphomas (DLBCL). Blood (ASH Annual Meeting Abstracts 2014) 124(21), 2014.
76. Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Chen W, Zhang L, Badillo M. Ibrutinib and Rituximab are an Efficacious and Safe Combination in Relapsed Mantel Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 2014.
77. Xu J, David RE, Zhiqiang Wang, Westin J. Selinexor (KPT-330) is Not Cross-Resistant with Chemotherapy and Demonstrates Strong Synergy with Targeted Therapy in DLBCL. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 2014.
78. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JR, Kwak LW, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32:5s,((suppl; abstr 8528)). e-Pub 2014.
79. Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Bravo VMV, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol 32:5s, 2014:(suppl; abstr 8508). e-Pub 2014.
80. Ahmed MA, Barac R, Medeiros LJ, Ma L, Fayad L, Romaguera JE, Oki Y, Rodriguez MA, Pinnix C, Kwak LW, Hagemeister FB, Davis RE, Westin JR. Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience. J Clin Oncol 32:5s:(suppl; abstr 8564). e-Pub 2014.
81. Saliba RM, Xu-Monette ZY, Rondon G, Valverde R, Korbling M, Gulbis AM, Anderlini P, Sairah A, Hosing CM, Popat UR, Kebriaei P, Fayad LE, Westin JR, Turturro F, Medeiros LJ, Champlin RE, Young KH. Outcomes following Autologous Stem Cell Transplantation (ASCT) in in Patients with Germinal Center B (GCB) and non-GCB Cell-Like Diffuse Large B cell Lymphomas (DLBCL) According to Conditioning with BEAM-Rituximab (Standard vs. High-Dose) vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood (ASH Annual Meeting Abstracts) 2013 122(21):3350, 2013.
82. Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience Submitted. Blood (ASH Annual Meeting Abstracts) 2013 122(21):1776, 2013.
83. Flinn I, Berdeja J, Friedberg JW, Casulo C, Thieblemont C, Morschhauser F, Westin JR, Seetharam S, Hellemans P, Smit H, de Vries R, Dauphinee E, Badamo-Dotzis J, Fourneau N, Oki Y. Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Patients With CD20-Positive B-Cell non-Hodgkin’s lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2013 122(21):852, 2013.
84. Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood (ASH Annual Meeting Abstracts) 2013 122(21):3028, 2013.
85. Garrido-Laguna I, Velez-Bravo V, Falchook GS, Subbiah V, Hong DS, Oki Y, Westin JR, Nunez CA, Fayad LE, Kwak LW, Shpall EJ, Wheler JJ, Liang W, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. Blood (ASH Annual Meeting Abstracts) 2013 122(21):3048, 2013.
86. Fanale MA, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Younes A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood (ASH Annual Meeting Abstracts) 122(21):252, 2013.
87. Jason R. Westin, Min Zhang, Seema Rawal, Larry W. Kwak, Sattva S. Neelapu, and R. Eric Davis. Integrated Analysis Of Genomic and Gene Expression Profiles In Follicular Lymphoma Reveals Subsets and Driver Genes Of Potential Microenvironmental Importance. Blood (ASH Annual Meeting Abstracts) 2013 122(21):2487, 2013.
88. Westin J., Chu F., Fayad L, Kwak LW, Fowler NH, Romaguera J., Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu SS. Final Update of Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Hematological Oncology Volume 31(Issue S1), 2013.
89. Westin J., Chu F., Fayad L, Kwak LW, Fowler NH, Romaguera J., Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 120:Abstract 793, 2012.
90. Chu F., Westin J., Zhang M, Feng L, Baladandayuthapani V, Wang Z., Allen R, Wallace M., Vence LM, Radvanyi L, Kwak LW, Rotem-Yehudar R, Davis RE, and Neelapu SS.. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma treated with CT-011, a Humanized anti-PD-1 Monoclonal. Blood (ASH Annual Meeting Abstracts) 120:Abstract 162, 2012.
91. Oki Y., Westin J., Fowler N, Neelapu S, McLaughlin P, Kwak LW, Romaguera J, Fanale M, Rodriguez MA, Orlowski RZ, Wang M, Ouzanian S. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 12:Abstract 3707, 2012.
92. Westin J., Fu S., Hong D., Helgason T., Culotta C., Angelo L., Ouyang F., Westin S., Kurzrock R.. Validation of the Phase 0 Concept. J Clin Oncol 29:(suppl; abstr TPS143), 2011.
93. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Prior to Receiving Frontline Therapy Presented at the 2010 14th Annual International Congress on Hematologic Malignancies, 2010.
94. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. J Clin Oncol 28(no. 15_suppl 9103), 2010.
95. Westin J., Chu F., Foglietta,M., Rodionov G., Rotem-Yehudar R., Neelapu SS.. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. J Clin Oncol 28(15_suppl TPS305), 2010.
96. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F.. Zoledronic acid treatment of frontline lymphoma patients; Prevention of bone loss Poster presentation at the Hematologic Malignancies 2010 - Sixth International Conference, 2010.
97. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F.. The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy. Clin Lymphoma Myeloma 9((6)):E30, 2009.
98. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood (ASH Annual Meeting Abstracts) 114:Abstract 3922, 2009.
99. Westin J., Saliba R., de Lima M, Alousi A., Hosing C., Qazilbash M, Khouri I., Shpall E., Champlin R. Couriel, D.. Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD). Blood (ASH Annual Meeting Abstracts) 110:Abstract 5015, 2007.

Book Chapters

1. Westin, JR. "Multidisciplinary Approach to Cancer: A Medical Oncologists View.". In: Oncologic Imaging: A Multidisciplinary Approach, 2nd Edition. Elsevier, 2022.
2. Steiner R, Westin JR. Chapter 8: Aggressive B-Cell Lymphomas. In: The MD Anderson Manual of Medical Oncology, Fourth Edition, 2022.
3. Nair R, Westin J. CAR T cells. In: Adv Exp Med Biol. Springer, 215-233, 2021.
4. Nair R, Westin JR. CAR T cells. In: Advances in Experimental Medicine and Biology. Springer, 215-233, 2020.
5. Westin JR, Konoplev SN, Fayad LE, Medeiros LJ. Chapter 8: Aggressive B-Cell Lymphomas. In: The MD Anderson Manual of Medical Oncology, Third Edition. 3rd. McGraw-Hill: New York, 2016.
6. Liu, X, Westin J. "Targeted Therapy of Lymphomas". In: Handbook of Targeted Cancer Therapy. 1st. Lippincott Williams & Wilkins, 2014.
7. Westin J, Kantarjian H, Kurzrock R. "Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes". In: 2012 ASCO Educational Book, ASCO Annual Meeting, 2012.
8. Westin J, Romaguera J. "Multidisciplinary Approach to Cancer: A Medical Oncologists View.". In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon, 2010.
9. Westin J, Hagemeister R, Fanale M.. "Hodgkin Lymphoma". In: The MD Anderson Manual of Medical Oncology. Second edition, 2009.

Letters to the Editor

1. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. Br J Haematol 165: 146-7, 2014.
2. Thompson MA, Westin JR, Hagemeister FB. Bone mineral density screening should be routine in lymphoma patients. Ann Oncol 25: 913-4, 2014.
3. Thompson MA, Westin JR, Hagemeister FB. BMD Screening should be routine in lymphoma-Response to Paccou et al. Annals of Oncology, 2014.